Novo Nordisk’s Stock Went On A Crash Diet, And Investors Demonstrated Their Love For Oura

from The Finimize Daily Brief · host Finimize

Novo Nordisk’s shares slimmed way down as investors felt disappointed by its latest obesity drug trial, while Oura raised $200 million from investors – proving it’s not just celebrities and executives who adore the Finnish smart rings.Today’s stories:Novo Nordisk’s Stock Went On A Crash Diet After The Firm’s Latest Clinical TrialInvestors Demonstrated Their Love For Oura, Lifting The Smart Ring Brand’s ValuationTry Finimize Pro

Episode metadata supplied by the publisher feed · Published Dec 21, 2024

Embed this episode

Attribution link and audio player

Ready to play

Novo Nordisk’s Stock Went On A Crash Diet, And Investors Demonstrated Their Love For Oura

0:00 5:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Finimize Daily Brief?

This episode is 5 minutes long.

When was this The Finimize Daily Brief episode published?

This episode was published on December 21, 2024.

Can I download this The Finimize Daily Brief episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!